Healthcare Biz Rewind: StemCells DOUBLES Its Value, Anthera POPS

Here are some of Tuesday’s top stories:

StemCells Inc. (NASDAQ:STEM) shares soar more than 100 percent following the news that the results of preclinical trials which showed that transplanting its proprietary human neural stem cells “restored memory and enhanced synaptic function in two animal models relevant to Alzheimer’s disease.” The data were presented at the Alzheimer’s Association International Conference.

Don’t Miss: Johnson & Johnson Books PROFIT, Revenue Lighter.

AstraZeneca Group P.L.C. (NYSE:AZN) plans to carry out a worldwide evaluation of its Brilinta heart treatment, using a sample of 11,500 people suffering from peripheral artery disease. The trial will contrast Brilinta, which is approved for acute-coronary syndrome patients, against Plavix, which is sold by Bristol-Myers Squibb Company (NYSE:BMY) and Sanofi-Aventis (NYSE:SNY).

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) move markedly up again Tuesday after announcing that its final set of clinical data from Phase 2b PEARL-SC trials successfully met its primary endpoint in patients suffering from systemic lupus erythematosus. The tests indicated that sustained and greater treatment using PEARL-SC scored higher in the SELENA-SLEDAI disease-scoring index against a placebo, and also that patients reported longer periods between symptoms.

Don’t Miss: Abbott Labs Quarterly Earnings on Deck.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.